TAIPEI, Taiwan, Oct. 4, 2020 /PRNewswire/ — TaiGen Biotechnology Company, Limited (“TaiGen”) announced today that it has filed an Investigational New Drug (IND) application with the US FDA for its influenza antiviral TG-1000.
TG-1000 is a novel pan-influenza antiviral, which interrupts viral replication and transmission via a cap-snatching mechanism and is able to do this effectively against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant viruses. The first US patent for TG-1000 was successfully prosecuted and granted by the United States Patent and Trademark Office on Jan 14th, 2020.
A Phase 1 trial for in China was initiated by TaiGen in July 2020 and has successfully completed the first 4 groups in the single ascending dose part. A Phase 2 protocol has also been submitted to the institutional review board (IRB) of China-Japan Friendship Hospital in Beijing last month.
“We are excited about the IND filing in the US for the internally developed TG-1000 which has the potential to be a single dose treatment for influenza,” said Kuo-Lung Huang, the Chairman and CEO of TaiGen, “TG-1000 IND filing demonstrates yet again TaiGen’s capacity and experience in research and development of NCEs.”
About TaiGen Biotechnology
TaiGen Biotechnology is a leading research-based and market-driven biotechnology company in Taiwan with a wholly-owned subsidiary in Beijing, China. In addition to TG-1000, TaiGen has three other in-house discovered NCEs: Taigexyn®, a novel non-fluorinated quinolone available in both oral and intravenous formulations, TG-3000, a chemokine receptor antagonist for stem cell transplantation and chemosensitization, and Furaprevir, a HCV protease inhibitor for treatment of chronic hepatitis infection. Taigexyn® is already on the market in the mainland China and Taiwan, TG-3000 has completed Phase 2 clinical studies, and Furaprevir is currently in Phase 3 clinical development.
SOURCE TaiGen
For decades, women’s health was treated as a collection of specialty concerns rather than an…
Brain health does not have an evidence problem. The science arrived years ago, and it…
Walk the buffet line at any environmental conference these days and you’ll notice something. The…
A short LinkedIn video of Steve Jobs recently caught my attention because it speaks directly…
Bill Curry, 65, raises cattle on the same land in rural Oklahoma once owned by…
You’re at the dinner table, and someone starts chewing. Nothing loud, nothing unusual. But something inside…
This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.
Read More